Results 271 to 280 of about 598,741 (306)
Some of the next articles are maybe not open access.
2011
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases.
Yixuan, Gong, William, Pao
openaire +2 more sources
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases.
Yixuan, Gong, William, Pao
openaire +2 more sources
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nature Reviews Clinical Oncology, 2022Lecia V Sequist, Jessica J Lin
exaly
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Nature Reviews Clinical Oncology, 2021Alex Friedlaender +2 more
exaly
EGFR signaling in renal fibrosis
Kidney International Supplements, 2014Shougang Zhuang, Na Liu
exaly
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nature Reviews Clinical Oncology, 2009Nicola Normanno +2 more
exaly